

LIST OF CONTENT

LIST OF CONTENT	v
LIST OF TABLES	vii
LIST OF FIGURES	viii
LIST OF ABBREVIATIONS	ix
ABSTRAK	x
ABTRACT	xi
CHAPTER I INTRODUCTION	1
1.1. Background.....	1
1.2. Formulation of Problem.....	10
1.3. Research purposes	11
1.4. Authenticity of Research	11
1.5. Benefits of the Research	12
CHAPTER II LITERATURE REVIEW	14
2.1. Literature Review	14
2.1.1. Overview and epidemiology of diabetes mellitus (DM)	14
2.1.2. Complications of Uncontrolled DM	15
2.1.3. Drug related problems in T2DM with and without HTN	17
2.1.4. PCNE DRPs Classification.....	20
2.2. Theoretical Framework.....	22
2.3. Conceptual Framework.....	23
CHAPTER III METHODOLOGY	24
3.1. Type and Design of Research	24
3.2. Research Variables	25
3.3. Operational Definition	28
3.4. Materials and Tools of Research	33
3.5. Research Method	33
3.6. Result Analysis	35
3.7. Research Ethics.....	35

CHAPTER IV. RESEARCH RESULTS AND DISCUSSION.....	36
4.1. Research Results.....	36
4.1.1. Baseline Characteristics of Patients.....	36
4.1.1.1. Demographic characteristics of patients.....	38
4.1.1.2. Clinical characteristics of patients.....	39
4.1.2. Drug Related Factors	40
4.1.2.1. Drug related factors in patients with DM group.....	42
4.1.2.2. Drug related factors in patients with DM+HTN group	42
4.1.3. Drug Related Problems.....	44
4.1.3.1. Drug related factors in patients with DM group.....	44
4.1.3.2. Drug related problems in DM+HTN	46
4.1.4. Drug utilization in inpatients having T2DM with and without HTN at RSA UGM Hospital.....	48
4.1.4.1. Antidiabetic drug utilization in T2DM inpatients	49
4.1.4.2. Antihypertensive drug utilization in T2DM inpatients.	50
4.1.5. The association of diagnosis and the risk factors with DRPs	51
4.2. Discussion.....	54
4.2.1. Baseline characteristics.....	55
4.2.2. Drug related factors	57
4.2.3. Drug related problems	61
4.2.4. Drug utilization	67
4.2.5. The association between diagnosis and risk factors with DRPs.	69
CHAPTER V. CONCLUSIONS AND SUGGESTIONS.....	73
5.1. Conclusion	73
5.2. Suggestion	74
References	75
Appendix 1. Ethics committee approval	81
Appendix 2. DM+HTN data	82
Appendix 3. DM data.....	83